Should I buy or sell Cabaletta Bio stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks .

What is Cabaletta Bio's stock price target for 2024?

10 Wall Street research analysts have issued 1-year price targets for Cabaletta Bio's stock. Their CABA share price targets range from $10.00 to $50.00. On average, they anticipate the company's share price to reach $27.64 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts .

How have CABA shares performed in 2023?

Cabaletta Bio's stock was trading at $9.25 at the beginning of 2023. Since then, CABA stock has increased by 75.5% and is now trading at $16.23. View the best growth stocks for 2023 here .

Are investors shorting Cabaletta Bio?

Cabaletta Bio saw a decline in short interest in November. As of November 15th, there was short interest totaling 5,060,000 shares, a decline of 19.4% from the October 31st total of 6,280,000 shares. Based on an average daily volume of 788,600 shares, the short-interest ratio is currently 6.4 days. View Cabaletta Bio's Short Interest .

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our CABA earnings forecast .

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY) . Invesco DWA SmallCap Momentum ETF (DWAS) .

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC) , Editas Medicine (EDIT) , Kaleido Biosciences (KLDO) , Sorrento Therapeutics (SRNE) , Homology Medicines (FIXX) , Skyworks Solutions (SWKS) , CrowdStrike (CRWD) , Precision BioSciences (DTIL) , Invitae (NVTA) and Pfizer (PFE) .

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (9.94%), Lynx1 Capital Management LP (4.91%), Redmile Group LLC (4.14%), Jennison Associates LLC (3.57%), Invesco Ltd. (1.99%) and Northern Trust Corp (0.70%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends .

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Cabaletta Bio Stock Price, News & Analysis (NASDAQ:CABA)

$16.23

+0.24 (+1.50%)

(As of 12/8/2023 ET)

Compare

Today's Range: $15.35
▼
$16.56
50-Day Range: $12.22
▼
$18.70
52-Week Range: $5.11
▼
$19.34

Volume: 983,158 shs
Average Volume: 1.73 million shs
Market Capitalization: $695.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.64

Cabaletta Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.3% Upside
$27.64 Price Target
Short Interest: Healthy
11.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: Selling Shares
$340,230 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.59) to ($1.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

157th out of 942 stocks

Biological Products, Except Diagnostic Industry

25th out of 161 stocks

4.5

Analyst's Opinion

Consensus Rating
Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.64, Cabaletta Bio has a forecasted upside of 70.3% from its current price of $16.23.
Amount of Analyst Coverage
Cabaletta Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
11.81% of the outstanding shares of Cabaletta Bio have been sold short.
Short Interest Ratio / Days to Cover
Cabaletta Bio has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Cabaletta Bio has recently decreased by 19.43%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cabaletta Bio does not currently pay a dividend.
Dividend Growth
Cabaletta Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CABA.

3.3

News and Social Media Coverage

News Sentiment
Cabaletta Bio has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.
Search Interest
19 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.
MarketBeat Follows
11 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $340,230.00 in company stock.
Percentage Held by Insiders
12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($1.59) to ($1.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cabaletta Bio is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cabaletta Bio is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cabaletta Bio has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cabaletta Bio Stock (NASDAQ:CABA)

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CABA Stock News Headlines

December 3, 2023 | americanbankingnews.com

Cabaletta Bio (NASDAQ:CABA) Shares Gap Down to $16.05

December 2, 2023 | americanbankingnews.com

Cabaletta Bio, Inc. to Post FY2023 Earnings of ($1.61) Per Share, William Blair Forecasts (NASDAQ:CABA)

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 1, 2023 | americanbankingnews.com

Cabaletta Bio (NASDAQ:CABA) Research Coverage Started at William Blair

November 30, 2023 | americanbankingnews.com

Cabaletta Bio (NASDAQ:CABA) PT Lowered to $25.00 at Morgan Stanley

November 30, 2023 | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Cabaletta Bio (NASDAQ:CABA)

November 29, 2023 | americanbankingnews.com

Traders Purchase High Volume of Cabaletta Bio Put Options (NASDAQ:CABA)

November 28, 2023 | uk.finance.yahoo.com

Cabaletta Bio, Inc. (CABA)

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 28, 2023 | marketwatch.com

Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs

November 28, 2023 | msn.com

Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

November 28, 2023 | finance.yahoo.com

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 27, 2023 | msn.com

Cabaletta Bio (CABA) Price Target Increased by 8.76% to 30.09

November 15, 2023 | markets.businessinsider.com

Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know

November 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Cabaletta Bio (CABA)

November 10, 2023 | bizjournals.com

Lab Notes: Cabaletta Bio gets FDA nod to advance new drug; South Jersey firm raises $3.5M

November 9, 2023 | msn.com

Cabaletta Bio GAAP EPS of -$0.37 beats by $0.04

November 9, 2023 | finance.yahoo.com

Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress

November 9, 2023 | benzinga.com

Cabaletta Bio: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | marketwatch.com

Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis

November 6, 2023 | markets.businessinsider.com

Cabaletta Bio Gets FDA's Nod For CABA-201 INDA For Generalized Myasthenia Gravis

November 6, 2023 | finance.yahoo.com

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

November 6, 2023 | finance.yahoo.com

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

November 1, 2023 | msn.com

Cabaletta Bio (CABA) Price Target Increased by 11.47% to 27.67

October 30, 2023 | finance.yahoo.com

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

October 25, 2023 | msn.com

Cantor starts Cabaletta at overweight, cites "strong" position in CART-T drugs

See More Headlines

Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CABA
CUSIP: N/A
CIK: 1759138
Web: www.cabalettabio.com
Phone: 267-759-3100
Fax: N/A
Employees: 92
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.64
High Stock Price Target: $50.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +70.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.05%
Return on Assets: -43.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.65
Quick Ratio: 15.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.60 per share
Price / Book: 4.51

Miscellaneous

Outstanding Shares: 42,849,000
Free Float: 37,566,000
Market Cap: $695.44 million
Optionable: Not Optionable
Beta: 2.42

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Steven A. Nichtberger M.D. (Age 62)
Co-Founder, Chairman, CEO & President
Comp: $970.6k
Dr. Gwendolyn K. Binder Ph.D. (Age 48)
President of Science & Technology
Comp: $692.99k
Dr. David J. Chang FACR (Age 60)
M.D., M.P.H., Chief Medical Officer
Comp: $676.74k
Dr. Michael C. Milone M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
Dr. Aimee Payne M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
Mr. Anup Marda M.B.A. (Age 46)
Chief Financial Officer
Comp: $548.2k
Dr. Samik Basu M.D.
Chief Scientific Officer
Mr. Michael Gerard J.D. (Age 43)
General Counsel & Secretary
Ms. Heather Harte-Hall M.Sc.
Chief Compliance Officer
Ms. Martha O'Connor
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CABA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings or view top-rated stocks.
What is Cabaletta Bio's stock price target for 2024?: 10 Wall Street research analysts have issued 1-year price targets for Cabaletta Bio's stock. Their CABA share price targets range from $10.00 to $50.00. On average, they anticipate the company's share price to reach $27.64 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price.
View analysts price targets for CABA or view top-rated stocks among Wall Street analysts.
How have CABA shares performed in 2023?: Cabaletta Bio's stock was trading at $9.25 at the beginning of 2023. Since then, CABA stock has increased by 75.5% and is now trading at $16.23.
View the best growth stocks for 2023 here.
Are investors shorting Cabaletta Bio?: Cabaletta Bio saw a decline in short interest in November. As of November 15th, there was short interest totaling 5,060,000 shares, a decline of 19.4% from the October 31st total of 6,280,000 shares. Based on an average daily volume of 788,600 shares, the short-interest ratio is currently 6.4 days.
View Cabaletta Bio's Short Interest.
When is Cabaletta Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CABA earnings forecast.
How were Cabaletta Bio's earnings last quarter?: Cabaletta Bio, Inc. (NASDAQ:CABA) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02.

What ETFs hold Cabaletta Bio's stock?: ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS).
What other stocks do shareholders of Cabaletta Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).
When did Cabaletta Bio IPO?: (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.
Who are Cabaletta Bio's major shareholders?: Cabaletta Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (9.94%), Lynx1 Capital Management LP (4.91%), Redmile Group LLC (4.14%), Jennison Associates LLC (3.57%), Invesco Ltd. (1.99%) and Northern Trust Corp (0.70%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends.
How do I buy shares of Cabaletta Bio?: Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CABA) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial